CX3CL1 and systemic sclerosis: Thus, our findings suggest that anti-CX3CL1 mAb therapy that inhibits the infiltration of macrophages into the tissue is a rational strategy for the treatment of skin fibrotic disorders, such as Scl-cGVHD and/or SSc.